Role of trospium chloride in brachytherapy-related detrusor overactivity.
OBJECTIVE
After prostate brachytherapy, pronounced urinary irritative symptomatology occurs in a substantial minority of patients. In this study, we evaluated the impact of trospium chloride in prostate brachytherapy patients with symptoms consistent with an overactive bladder (OAB).


METHODS
From January 1999 through December 2005, 69 permanent prostate brachytherapy patients were identified who received trospium as first-line treatment for OAB. The median interval from implant to initiation of trospium was 23.4 months. Before trospium, we obtained a postvoid residual urine assessment (PVR) and International Prostate Symptom Score (IPSS) for all patients. IPSS resolution was defined as a return to within 2 points of the pre-brachytherapy value and individual IPSS question resolution was defined by a decrease of at least 1 point.


RESULTS
The mean patient age was 66.0 years, with a pre-brachytherapy prostate volume of 31.0 cm(3) and a mean preimplant IPSS of 6.5. At trospium initiation, the mean IPSS was 9.6 with a mean PVR of 12.3 mL. IPSS normalization was documented in 55 (79.7%) patients. Twelve months after trospium initiation, the IPSS had decreased by a mean of 4.3 points with the improvement most pronounced for urgency. After trospium, no clinically significant differences were noted in the mean PVR. Twenty-two patients discontinued trospium as a result of the absence of a clinical response or pharmacologic side effects, or after complete resolution of symptoms.


CONCLUSIONS
Nearly 80% of patients with brachytherapy-related detrusor overactivity responded favorably to trospium with improvements in IPSS (especially urgency). This was accomplished with an acceptable morbidity profile.
Bittner
Nathan
N
Department of Radiation Oncology, University of Washington, Seattle, Washington, USA.
Merrick
Gregory S
GS
Brammer
Sarah
S
Niehaus
Angela
A
Wallner
Kent E
KE
Butler
Wayne M
WM
Allen
Zachariah A
ZA
Galbreath
Robert W
RW
D000368:Aged; D001561:Benzilates; D001918:Brachytherapy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009662:Nortropanes / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology*
D001561:Benzilates; D009662:Nortropanes; C003330:trospium chloride